| Document |
Document Title |
|
WO/2022/147214A3 |
This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety — phosphorus coupling group (I). The cyclic disulfide moiety has the structure of (C-I), (C-II), or (C-III). This invention also relate...
|
|
WO/2022/147214A2 |
This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety — phosphorus coupling group (I). The cyclic disulfide moiety has the structure of (C-I), (C-II), or (C-III). This invention also relate...
|
|
WO/2022/054554A1 |
Provided is a highly active actinic-ray-sensitive acid generator which, upon irradiation with actinic rays, comes to have cationic-polymerization performance or crosslinking reaction performance and which enables curable compositions con...
|
|
WO/2022/047481A1 |
Disclosed herein are ring-in-ring photoluminescent complexes comprising a host cyclophane and a guest cyclophane threaded through the host cyclophane and methods of using and making the same. Further disclosed herein a method for tuning ...
|
|
WO/2021/237371A1 |
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected ...
|
|
WO/2021/241582A1 |
The present disclosure provides an agent for treating or preventing ophthalmopathy such as presbyopia, the agent containing as an active ingredient a sulfur-containing compound having a prescribed structure.
|
|
WO/2021/241246A1 |
Provided are a radiation-sensitive resin composition capable of exhibiting adequate levels of sensitivity, LWR performance, and CDU performance, and a method for forming a pattern. This radiation-sensitive resin composition contains a so...
|
|
WO/2021/212220A1 |
Isolated, pure, soluble isoform free recombinant human interferon alpha 2b (rhIFN α-2b). Methods of making the soluble isoform free rhIFN α-2b. Stable compositions and formulations of isoform free rhIFN α-2b are for administration gen...
|
|
WO/2021/181361A1 |
The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
|
|
WO/2021/172112A1 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition, represented by specific general formula (1), containing (A) a resin, and (B) a compound that produces an acid when irradiated with actinic...
|
|
WO/2021/162384A1 |
The present invention provides a novel compound capable of improving the luminous efficiency, stability, and lifespan of a device, an organic electric device using same, and an electronic device thereof.
|
|
WO/2021/135035A1 |
The present invention relates to a high-performance sky-blue thermally activated delayed fluorescent material, and a preparation method therefor and an application thereof. According to the present invention, the problems in the prior ar...
|
|
WO/2021/135207A1 |
Disclosed are a nitrogen-containing compound as represented by chemical formula 1, an electronic component, and an electronic device, the nitrogen-containing compound being capable of improving the performance of the electronic component...
|
|
WO/2021/120838A1 |
Disclosed is an organic compound, an electronic device containing the organic compound, and an electronic apparatus having the electronic device. A main structure of the organic compound is a fused heterocyclic aromatic group containing ...
|
|
WO/2021/104432A1 |
Provided is a preparation method for an L-ornithine composite salt. The preparation method comprises the following steps: (1) taking an L-ornithine salt solution as a raw material to prepare a free L-ornithine solution by means of a bipo...
|
|
WO/2021/100654A1 |
A compound which is represented by formula (1). (In the formula, R1 represents a hydrogen atom or a methyl group; R2 represents an optionally substituted aromatic ring group or an alkyl group that is substituted by an optionally substitu...
|
|
WO/2021/081634A1 |
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...
|
|
WO/2021/081172A1 |
Coordination complexes of tetrathiafulvalene-based dithiolene linkers, such as tetrathiafulvalene-2,3,6,7-tetrathiolate (TTFtt), and their oxidation products are described. The coordination complexes can include metals such as tin or sil...
|
|
WO/2020/261886A1 |
An ultraviolet ray absorber represented by general formula (1) and a use therefor. In general formula (1), R11 represents a monovalent substituent group. n is 1 or 2. W1 and W2 each independently represent a hydrogen atom, a cyano group,...
|
|
WO/2020/227276A1 |
The disclosure provides thianthrene derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several thianthrene structures are described, inclu...
|
|
WO/2020/213693A1 |
The present disclosure provides a therapeutic or prophylactic agent for an ophthalmic disease such as presbyopia, said agent comprising, as an active ingredient, a lipoic acid prodrug having a specific structure.
|
|
WO/2020/187155A1 |
Use of an apocynin dimer analogue derivative in preparing a medicament or a health care product for preventing and treating Parkinson's disease. The structure of the apocynin dimer analogue derivative is as shown in formula I. The apocyn...
|
|
WO/2020/121823A1 |
The present invention addresses the problem of providing: a liquid crystal composition which is to be used in an active drive display element and improves chromatic dispersion properties; a display element which uses said liquid crystal ...
|
|
WO/2020/109148A1 |
A photoinitiator selected from the group consisting of an acylphosphine oxide, a α-hydroxy-ketone and a α-amino-ketone, characterized in that the photoinitiator includes at least one aliphatic disulfide as functional group.
|
|
WO/2020/106028A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/094673A1 |
Thianthrene derivative of the Formula (I): wherein R1 to R8 may be the same or different and are selected from hydrogen, Cl, F, a partially or fully fluorinated C1 to C6 alkyl group, and wherein n is 0 or 1, with the proviso that at leas...
|
|
WO/2020/078369A1 |
Provided are a phenolic derivative, preparation method therefor and use thereof. The phenolic derivative has a structure as shown in formula (I), and the definitions of the groups therein are shown in the description. The phenolic deriva...
|
|
WO/2020/041871A1 |
This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-β-hydroxybutyl-R-β-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease....
|
|
WO/2020/035826A1 |
The present invention discloses 1,2-dithiolone compounds of the formula (I), wherein, A, Cy, R, R1, R2a and R2b have the same meanings as defined in the description. The present invention further discloses methods for their preparation a...
|
|
WO/2019/241644A1 |
The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
|
|
WO/2019/227202A1 |
Disclosed are pharmaceutical salts and co-crystals of pentoxifylline, clonidine and linsidomine with caffeic acid, protocatechuic acid or α-lipoic acid, and method for preparing thereof. Also disclosed are topical compositions comprisin...
|
|
WO/2019/178689A1 |
A method for promoting weight management in a mammal is provided, comprising administering to the mammal a composition comprising at least one weight loss agent and at least one mitochondria enhancing agent. The weight loss agent may be ...
|
|
WO/2019/161280A1 |
The present disclosure relates to methods and intermediates useful for preparing a compound of formula (I): (I) or a co-crystal, solvate, salt or combination thereof.
|
|
WO/2019/150341A1 |
The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination w...
|
|
WO/2019/149091A1 |
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...
|
|
WO/2019/142539A1 |
A composition comprising a compound represented by formula (I) and a compound represented by formula (III); a curable composition; and a compound. R11 represents an unsubstituted alkyl group. R12, R13, R32, and R33 each independently rep...
|
|
WO/2019/129403A1 |
The present invention concerns the field of neurodegenerative diseases, and in particular relates to compounds, pharmaceutical compositions and their uses in the protection of neuronal cells from inflammation and from oxidative stress in...
|
|
WO/2019/124154A1 |
Provided are: a polymerizable liquid-crystal compound suitable for producing positive-C-plate retarder films which have excellent heat resistance and reverse wavelength dispersion characteristics; a polymerizable liquid-crystal compositi...
|
|
WO/2019/111853A1 |
The present invention addresses the problem of providing a method for producing a dicarboxylic acid monoester with excellent production efficiency, a method for producing a polymerizable liquid crystal compound, and a novel dicarboxylic ...
|
|
WO/2019/108033A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light emitting element comprising the same.
|
|
WO/2019/087054A1 |
The present invention relates to novel pharmaceutical composition comprising DPP-4 inhibitor, Alpha-lipoic acid and Vitamin B12. The synergism of DPP-4 inhibitor, Alpha- lipoic acid and Vitamin B12 helps in the treatment of diabetes and ...
|
|
WO/2019/071353A1 |
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...
|
|
WO/2019/061299A1 |
Provided is a one-step amination reaction for producing an aminomethyl substituted heterocycloalkane, notably (tetrahydrofuran-2, 5-diyl) dimethanamine.
|
|
WO/2019/065043A1 |
Provided are a compound production method capable of producing a benzothiol compound having little coloration, a composition, and a curable composition. The method is for producing a compound represented by formula (1) and comprises reac...
|
|
WO/2019/044863A1 |
The present invention provides a cured product which is obtained by curing a curable composition that contains a compound represented by general formula 1, and which has a birefringence ∆n (587 nm) satisfying 0.00 ≤ ∆n (587 nm) ≤...
|
|
WO/2019/017445A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal compound which is used in formation of an optically anisotropic membrane having excellent reverse wavelength dispersibility; a polymerizable liquid ...
|
|
WO/2019/017444A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal compound which is used in formation of an optically anisotropic membrane having excellent reverse wavelength dispersibility and excellent moist heat...
|
|
WO/2018/167677A1 |
An object of the present invention is to provide a dithiolane compound or a salt or an N-oxide thereof that controls diseases. The present invention provides a dithiolane compound represented by Formula (1) or a salt or an N-oxide thereo...
|
|
WO/2018/155498A1 |
The present invention addresses the problem of providing a polymerizable liquid crystal compound that exhibits superior solubility and is used to form an optically anisotropic film exhibiting superior durability, and a method of producin...
|
|
WO/2018/128800A1 |
The disclosure is directed to compounds of formula (I). Methods of using these compounds, particularly as antimicrobial agents, are also described
|
